Equities
  • Price (EUR)138.40
  • Today's Change0.00 / 0.00%
  • Shares traded15.00
  • 1 Year change-28.10%
  • Beta1.2880
Data delayed at least 15 minutes, as of Jul 04 2025 07:01 BST.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

IQVIA Holdings Inc. is a global provider of clinical research services, commercial insights and healthcare intelligence to the life sciences and healthcare industries. Its segments include Technology & Analytics Solutions, Research & Development Solutions and Contract Sales & Medical Solutions. The Technology & Analytics Solutions segment provides mission-critical information, technology solutions and real-world insights and services to the Company’s life science clients. The Research & Development Solutions segment primarily serves biopharmaceutical customers, and provides outsourced clinical research and clinical trial-related services. The Contract Sales & Medical Solutions segment provides healthcare provider (including contract sales) and patient engagement services to both biopharmaceutical customers and the broader healthcare market. It offers a set of strategic and implementation consulting services, including advanced analytics and commercial processes outsourcing services.

  • Revenue in USD (TTM)15.50bn
  • Net income in USD1.33bn
  • Incorporated2016
  • Employees89.00k
  • Location
    IQVIA Holdings Inc2400 ELLIS ROADDURHAM 27703United StatesUSA
  • Phone+1 (919) 998-2000
  • Fax+1 (302) 636-5454
  • Websitehttps://ir.iqvia.com/
More ▼

Mergers & acquisitions

Acquired companyDeal statusDateDate /
Deal status
IQV:NYQ since
announced
Transaction
value
Shanghai Illuminera Digital Technology Co LtdDeal completed26 Jul 202426 Jul 2024Deal completed-29.30%--
Data delayed at least 15 minutes, as of Jul 03 2025 18:00 BST.
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.